Compare BSVN & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BSVN | MYGN |
|---|---|---|
| Founded | 2004 | 1991 |
| Country | United States | United States |
| Employees | N/A | 2700 |
| Industry | Major Banks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 632.6M | 523.7M |
| IPO Year | 2018 | 1996 |
| Metric | BSVN | MYGN |
|---|---|---|
| Price | $55.97 | $5.47 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 9 |
| Target Price | ★ $63.33 | $5.90 |
| AVG Volume (30 Days) | 30.1K | ★ 1.7M |
| Earning Date | 10-15-2026 | 11-04-2026 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.18 | N/A |
| Revenue | N/A | ★ $771,400,000.00 |
| Revenue This Year | $10.97 | N/A |
| Revenue Next Year | $54.28 | N/A |
| P/E Ratio | $17.70 | ★ N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $38.29 | $2.74 |
| 52 Week High | $60.17 | $8.09 |
| Indicator | BSVN | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 36.86 | 46.99 |
| Support Level | $53.85 | $4.19 |
| Resistance Level | $57.23 | $5.52 |
| Average True Range (ATR) | 1.17 | 0.30 |
| MACD | -0.47 | -0.13 |
| Stochastic Oscillator | 6.35 | 0.00 |
Bank7 Corp is a full-service commercial bank focused on providing customers with exceptional service and meeting their banking needs through a variety of commercial and retail financial services. It offers deposit banking products, including commercial deposit services, commercial checking, money market, and other deposit accounts, and retail deposit services such as certificates of deposit, money market accounts, checking accounts, negotiable order of withdrawal accounts, savings accounts, and automated teller machine access. etc. It generates revenues from interest income from financial instruments and non-interest income and service charges on deposit accounts.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.